Sanofi teams up with UCB for research in immune-mediated diseases


Tuesday, 11 Mar 2014 02:01am EDT 

Sanofi SA:Enters into strategic collaboration with UCB for discovery and development of anti-inflammatory small molecules to treat wide range of immune-mediated diseases in areas such as gastroenterology and arthritis.Costs and profits shared 50/50.UCB entitled to initial upfront, preclinical and clinical development milestone payments from Sanofi, potentially above 100 million euros. 

Company Quote

75.38
-0.79 -1.04%
19 Dec 2014